
Innate Pharma Reports Strong Preclinical Anti-Tumor Activity of IPH4502 Antibody-Drug Conjugate at AACR 2025
Innate Pharma Presents Compelling Preclinical Data on Novel ADC Candidate IPH4502 Targeting Nectin-4 at AACR 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a biotechnology company specializing in the…












